Teva Launches Generic Salmeterol in the U.K. To Compete With GSK's Serevent
This article was originally published in The Pink Sheet Daily
The "first to market" generic salmeterol inhaler, which Teva is pricing at a 15% discount to Serevent, might help to pave the way for a much more lucrative opportunity - generic Advair.
You may also be interested in...
With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.
FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.
The company is borrowing a page, and a law firm, from GlaxoSmithKline’s 2009 citizen petition asking FDA to impose conditions on generic Advair.